Introduction
============

Leukemia is a group of malignant diseases of the hematopoietic system, with an estimated 54,270 new cases and 24,450 deaths expected in the USA in 2015.[@b1-ott-8-1009] Although the incidence of leukemia increases gradually, with age the most prominent risk factor, the etiology and mechanisms underlying the pathogenesis of leukemia are not yet fully understood.[@b2-ott-8-1009] Epidemiological studies have found that advanced age, radiation, smoking, and exposure to chemical carcinogens are risk factors which contribute to the genesis of leukemia.[@b3-ott-8-1009]--[@b5-ott-8-1009] However, only a small proportion of people exposed to these risk factors develop leukemia, suggesting that host genetic factors might play an important role.[@b6-ott-8-1009] Recent genome-wide association studies have identified the presence of inherited genetic susceptibility to this disease.[@b7-ott-8-1009]--[@b9-ott-8-1009] Therefore, multiple factors are considered implicated in the etiology of leukemia, including exogenous or endogenous exposure, genetic susceptibility, and chance.[@b2-ott-8-1009]

The human adenosine triphosphate-binding cassette, subfamily B, member 1 (*ABCB1*) gene, also named multidrug-resistance 1 (*MDR1*) gene, is located at 7q21.1, with 28 exons encoding a 170 kDa membrane transporter called P-glycoprotein (P-gp). The presence of a highly conserved adenosine triphosphate (ATP)-binding site in two homologous halves as well as the linker region makes this protein a member of the adenosine triphosphate-binding cassette (ABC) superfamily.[@b10-ott-8-1009] P-gp acts as an efflux pump in an ATP-dependent fashion, transporting exogenous and endogenous substrates from the inside of cells to the outside. P-gp was first identified in human cancer cells as a protein responsible for resistance against many anticancer drugs. Subsequently, this efflux transporter has been found in various normal human tissues, including in the intestinal epithelium, adrenal gland, placenta, kidney, liver, capillary endothelial cells of the brain, and testes. Physiological expression of P-gp in excretory tissues provides a cellular defense mechanism against potentially harmful compounds.[@b10-ott-8-1009]--[@b12-ott-8-1009] *ABCB1* is polymorphic and at least 50 single-nucleotide polymorphisms (SNPs) have been identified within *ABCB1* gene locus.[@b13-ott-8-1009] C3435T at exon 26 is the most widely investigated SNP of *ABCB1* and has been associated with altered P-gp expression and activity in tissue studies including those on placenta, liver, and leukocytes.[@b14-ott-8-1009]--[@b16-ott-8-1009] There is increasing evidence that genetic variants of *ABCB1* affect P-gp activity and expression levels, and the alteration of P-gp transport activity results in decreased extrusion of harmful xenobiotics and cumulative cytotoxicity.[@b17-ott-8-1009],[@b18-ott-8-1009] The C3435T SNP in *ABCB1* has been associated with the development of various cancers, including breast cancer, hepatocellular carcinoma, and non-Hodgkin lymphoma.[@b19-ott-8-1009]--[@b21-ott-8-1009] Many case--control studies have been conducted to investigate whether the *ABCB1* C3435T polymorphism is associated with leukemia risk but these have yielded controversial results. Therefore, we performed a meta-analysis to accurately evaluate the effect of *ABCB1* C3435T polymorphism on leukemia susceptibility.

Materials and methods
=====================

Study identification
--------------------

A systematic literature search of the PubMed, Elsevier, China National Knowledge Infrastructure, and Wanfang databases was conducted to identify studies that explored the relationship between *ABCB1* C3435T polymorphism and leukemia risk. The search terms and keywords were as follows: "multidrug resistance gene" or "*MDR1*" or "*ABCB1*", "polymorphism" or "variant" or "mutant", and "leukemia" or "leukaemia" or "leukocythemia". No language restriction was applied and the latest search was undertaken on April 30, 2014. The references cited in the eligible studies were also examined to find additional studies. Two reviewers examined the retrieved literature independently and disagreement was resolved by discussion.

Inclusion criteria
------------------

All studies included in this meta-analysis had to meet the following criteria. They had to: (1) be case--control studies assessing the relationship between *ABCB1* C3435T polymorphism and leukemia risk; (2) have confirmed diagnosis in the case group; and (3) have genotype frequencies for both cases and controls available. Reviews, meta-analyses, case reports, and letters were excluded.

Data extraction
---------------

Two reviewers independently extracted information from each eligibility study and disagreements were addressed by discussion. The following data were extracted from each study: author(s), year of publication, country, ethnicity, source of controls, genotyping methods, sample size of cases and controls, genotype frequencies of the *ABCB1* C3435T polymorphism for cases and controls, and Hardy--Weinberg equilibrium (HWE) of control group.

Statistical analysis
--------------------

The HWE of the genotype distribution in the control groups was checked using the *χ*^2^ test and *P*-values \<0.05 were designated as deviations from HWE. The strength of association between *ABCB1* C3435T polymorphism and leukemia risk was assessed by odds ratios (ORs) with 95% confidence intervals (CIs) under the heterozygote model (CT vs CC), homozygote model (TT vs CC), dominant model (CT+TT vs CC), and recessive model (TT vs CC+CT). The significance of the combined OR was determined by the *Z* test. The Q-statistic test was used to evaluate the between-study heterogeneity. If *P*\<0.05, indicating that there was significant heterogeneity, the random-effects model (DerSimonian--Laird) was applied to combine the data, otherwise, the fixed-effects model (Mantel--Haenszel) was selected. Subgroup analyses were performed by ethnicity, age, and leukemia subtype to find the source of heterogeneity. Funnel plots were produced to evaluate publication bias and sensitivity analysis was performed by omission of studies not in agreement with HWE to assess the stability of the results. All the tests were two-sided and *P*-values \<0.05 were considered as statistically significant. The data analyses were performed using Review Manager software (v 5.2; The Cochrane Collaboration, Oxford, UK).

Results
=======

Characteristics of studies
--------------------------

In accordance with the inclusion criteria, a total of 17 publications with 2,431 leukemia cases and 3,028 controls were included in the meta-analysis presented here.[@b22-ott-8-1009]--[@b38-ott-8-1009] The main characteristics of included studies are summarized in [Table 1](#t1-ott-8-1009){ref-type="table"}. All of the 17 studies were case--control studies, 14 of which were population-based controls and the remaining three were hospital-based controls. All the cases had a confirmed diagnosis of leukemia and the controls were mainly matched for age and sex. Among the included studies, six studies were conducted in an Asian population,[@b25-ott-8-1009],[@b28-ott-8-1009],[@b31-ott-8-1009],[@b34-ott-8-1009],[@b36-ott-8-1009],[@b38-ott-8-1009] nine studies in a Caucasian population,[@b22-ott-8-1009]--[@b24-ott-8-1009],[@b26-ott-8-1009],[@b29-ott-8-1009],[@b30-ott-8-1009],[@b32-ott-8-1009],[@b33-ott-8-1009],[@b35-ott-8-1009] and two studies in a mixed population.[@b27-ott-8-1009],[@b37-ott-8-1009] The distribution of genotypes among the control groups in four studies was not in agreement with HWE.[@b22-ott-8-1009],[@b33-ott-8-1009],[@b35-ott-8-1009],[@b36-ott-8-1009]

Meta-analysis results
---------------------

[Table 2](#t2-ott-8-1009){ref-type="table"} lists the main results of this meta-analysis. When all the eligible studies were pooled into the meta-analysis, a significant association between *ABCB1* C3435T polymorphism and leukemia risk was observed under two genetic models (TT vs CC: OR=1.39, 95% CI=1.04--1.84, *P*=0.02; CT+TT vs CC: OR=1.20, 95% CI=1.06--1.36, *P*=0.004) ([Table 2](#t2-ott-8-1009){ref-type="table"}). Subgroup analyses were also performed to explore the effect of ethnicity, age, and leukemia subtype. When stratified by ethnicity, a significantly increased risk was observed in Caucasians (CT vs CC: OR=1.22, 95% CI=1.03--1.45, *P*=0.02; TT vs CC: OR=1.34, 95% CI=1.10--1.64, *P*=0.004; CT+TT vs CC: OR=1.27, 95% CI=1.08--1.49, *P*=0.004) ([Table 2](#t2-ott-8-1009){ref-type="table"}). Significant associations were also found in adult leukemia (CT vs CC: OR=1.46, 95% CI=1.17--1.83, *P*=0.001; CT+TT vs CC: OR=1.43, 95% CI=1.01--2.03, *P*=0.04) ([Table 2](#t2-ott-8-1009){ref-type="table"}, [Figure 1](#f1-ott-8-1009){ref-type="fig"}) and lymphocytic leukemia (TT vs CC: OR=1.73, 95% CI=1.19--2.51, *P*=0.004; TT vs CC+CT: OR=1.62, 95% CI=1.10--2.38, *P*=0.01; CT+TT vs CC: OR=1.28, 95% CI=1.10--1.48, *P*=0.001) ([Table 2](#t2-ott-8-1009){ref-type="table"}, [Figure 2](#f2-ott-8-1009){ref-type="fig"}).

Sensitivity analysis and publication bias
-----------------------------------------

Sensitivity analysis was performed by excluding the studies in which the distribution of genotypes in the control groups was not in agreement with HWE. The results show that the statistical significance was not changed, suggesting that the results of this meta-analysis are relatively stable and credible. Four funnel plots were produced to assess the publication bias and the shapes of funnel plots reveal no evidence of obvious asymmetry, indicating there is no statistical evidence of publication bias ([Figure 3](#f3-ott-8-1009){ref-type="fig"}).

Discussion
==========

At least 50 SNPs have been described in all 28 exons of the *ABCB1* gene and the C3435T (rs1045642) polymorphism is a synonymous variant with no effect on amino-acid change at codon 1142 (Ile1142Ile) in the second ATP-binding domain.[@b13-ott-8-1009],[@b17-ott-8-1009] Studies have shown that 3435T is associated with lower *ABCB1* expression levels and subsequently reduces P-gp activity and alters substrate specificity.[@b14-ott-8-1009],[@b39-ott-8-1009],[@b40-ott-8-1009] P-gp is not only expressed in tumor cells, but also in cells of several normal tissues. It was detected in the apical membranes of excretory tissues, such as the intestine, kidney, and liver, suggesting its role in the elimination of xenobiotics.[@b41-ott-8-1009],[@b42-ott-8-1009] Besides, P-gp is also expressed in peripheral leukocytes and hematopoietic stem cells from which acute myeloid leukemia originates, which indicates that *ABCB1* may play an important role in the etiology of leukemia.[@b43-ott-8-1009],[@b44-ott-8-1009] Functional polymorphisms in *ABCB1* may cause various human malignancies including leukemia. However, the exact biological mechanism for the association of *ABCB1* polymorphisms with leukemia risk still requires explanation through further studies.

Given the potential influence of this functional polymorphism on cancer susceptibility, many molecular epidemiological studies have been conducted to investigate the association between *ABCB1* C3435T polymorphism and leukemia risk. However, the results from different studies are controversial, which may be owing to different genetic backgrounds in individual studies. To synthetically evaluate the effect of *ABCB1* C3435T polymorphism on susceptibility to leukemia, we performed a meta-analysis of 17 case--control studies that assessed the relationship between *ABCB1* C3435T polymorphism and leukemia risk. In this meta-analysis, in overall comparisons under a homozygote model and dominant model, we found that the *ABCB1* 3435TT genotype significantly increases leukemia risk. When stratified by ethnicity, the results indicate that the individuals with a TT genotype in the C3435T of *ABCB1* had significantly increased risk of leukemia among Caucasian populations, but not in other ethnicities. An explanation for this is that the racial differences in leukemia incidence can partly be attributed to differences in genotype frequencies between different populations at *ABCB1* loci. In the subgroup analysis by age, we found significant association between *ABCB1* C3435T polymorphism and increased risk in adult leukemia in the heterozygote model and dominant model, but not in children with leukemia under any comparison models. When restricting the analysis to the subtype of leukemia, significant association was found in lymphocytic leukemia in the homozygote model, recessive model, and dominant model, but not in myeloid leukemia in any comparison model, which indicates that clinical type might have a critical effect on the association.

The results of this study show that *ABCB1* C3435T polymorphism might modify susceptibility to leukemia, which is consistent with the meta-analysis reported by Qian et al.[@b45-ott-8-1009] Since our study combined a total of 2,431 cases and 3,028 controls from 17 case--control studies, our results are more convincing.

Limitations
===========

Some limitations of this meta-analysis should be taken into consideration and caution is needed when the results are interpreted. First, non-differential misclassification bias is possible, as the controls were not uniformly defined. Population-based controls and hospital-based controls have different risks of evolving leukemia. Second, our analyses were based on estimates not adjusted for other risk factors such as folate-intake status, lifestyle, and environmental exposures, which might influence the combined results. Third, although subgroup analyses were performed by ethnicity, age, and leukemia subtype to find the sources of heterogeneity, significant heterogeneity still existed in some subgroups. The heterogeneity may have been caused by different lifestyles, exposure to different risk factors, and the different levels of exposure to risk factors. In addition, due to the limited original data, potential gene--gene and gene--environment interactions which have an important impact on leukemia risk were not evaluated in this study.

Conclusion
==========

This meta-analysis found that *ABCB1* C3435T polymorphism is associated with an increased risk of leukemia and is likely a risk factor facilitating leukemia development. However, well-designed case--control studies with larger sample size focusing on more ethnicities or leukemia subtypes are required to validate our findings in the future.
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###### 

Main characteristics of studies included in the meta-analysis

  Study                                  Year   Country                      Ethnicity   Illness       Design   Method(s)               Case   Control   CC   CT    TT    CC    CT    TT    HWE
  -------------------------------------- ------ ---------------------------- ----------- ------------- -------- ----------------------- ------ --------- ---- ----- ----- ----- ----- ----- ------
  Bektaş-Kayhan et al[@b33-ott-8-1009]   2012   Turkey                       Caucasian   Child ALL     PB       PCR-RFLP                47     68        11   26    10    11    44    13    0.01
  Gréen et al[@b35-ott-8-1009]           2012   Sweden                       Caucasian   Adult AML     PB       Sequencing              100    400       19   47    34    87    175   138   0.03
  Hattori et al[@b25-ott-8-1009]         2007   Japan                        Asian       Child ALL     PB       TaqMan^®^ SNP           118    96        39   50    29    40    46    10    0.54
  Jamroziak et al[@b23-ott-8-1009]       2006   Poland                       Caucasian   Adult AML     PB       PCR-RFLP                180    180       44   95    41    62    78    40    0.11
  Jamroziak et al[@b24-ott-8-1009]       2006   Poland                       Caucasian   Adult B-CLL   PB       PCR-RFLP                110    201       27   59    24    74    88    39    0.17
  Jamroziak et al[@b22-ott-8-1009]       2004   Poland                       Caucasian   Child ALL     PB       PCR-RFLP                113    175       43   36    34    70    71    34    0.04
  Leal-Ugarte et al[@b27-ott-8-1009]     2008   Mexico                       Mixed       Child ALL     PB       PCR-RFLP                107    111       18   65    24    15    59    37    0.26
  Liu[@b28-ott-8-1009]                   2008   People's Republic of China   Asian       Adult ALL     HB       PCR-RFLP                48     100       10   26    12    45    42    13    0.52
  Lü et al[@b34-ott-8-1009]              2012   People's Republic of China   Asian       Child ALL     HB       SNaPshot^®^ SNP         176    170       67   24    85    71    79    20    0.78
  Penna et al[@b32-ott-8-1009]           2011   Italy                        Caucasian   Adult B-CLL   PB       PCR-RFLP                125    125       26   59    40    45    57    23    0.51
  Rao et al[@b31-ott-8-1009]             2010   India                        Asian       ALL+AML       PB       PCR-RFLP                290    249       50   126   114   49    128   72    0.56
  Rocha et al[@b30-ott-8-1009]           2009   France                       Caucasian   AL+CL         HB       PCR-RFLP                107    107       30   56    21    29    56    22    0.60
  Semsei et al[@b29-ott-8-1009]          2008   Hungary                      Caucasian   Child ALL     PB       Single-base extension   378    189       86   177   115   54    84    51    0.13
  Singh et al[@b36-ott-8-1009]           2012   Singapore                    Asian       Adult CML     PB       Sequencing              38     275       13   15    10    65    114   96    0.01
  Urayama et al[@b26-ott-8-1009]         2007   USA                          Caucasian   Child ALL     PB       Single-base extension   294    369       81   140   73    100   178   91    0.51
  Vivona et al[@b37-ott-8-1009]          2012   Brazil                       Mixed       Adult CML     PB       PCR-RFLP                118    120       43   62    13    42    60    18    0.65
  Zhai et al[@b38-ott-8-1009]            2012   People's Republic of China   Asian       Child ALL     PB       SNaPshot SNP            82     93        39   34    9     40    40    13    0.56

**Abbreviations:** ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; HB, hospital based; HWE, Hardy--Weinberg equilibrium; PB, population based; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SNP, single-nucleotide polymorphism.

###### 

Results of meta-analysis for adenosine triphosphate-binding cassette, subfamily B, member 1 (*ABCB1*) C3435T polymorphism and leukemia risk

  Variable     N    CT vs CC            TT vs CC   TT vs CC+CT   CT+TT vs CC                                                                                            
  ------------ ---- ------------------- ---------- ------------- ------------------- -------- -------- ------------------- ------ -------- ------------------- -------- ------
  Overall      17   1.06 (0.85--1.31)   0.62       \<0.01        1.39 (1.04--1.84)   0.02     \<0.01   1.31 (0.99--1.72)   0.06   \<0.01   1.20 (1.06--1.36)   \<0.01   0.06
  Ethnicity                                                                                                                                                             
   Asian       6    0.88 (0.52--1.48)   0.63       \<0.01        1.81 (0.92--3.58)   0.09     \<0.01   1.86 (0.92--3.74)   0.08   \<0.01   1.18 (0.95--1.48)   0.13     0.05
   Caucasian   9    1.22 (1.03--1.45)   0.02       0.16          1.34 (1.10--1.64)   \<0.01   0.27     1.17 (0.99--1.39)   0.06   0.45     1.27 (1.08--1.49)   \<0.01   0.16
   Mixed       2    0.98 (0.62--1.53)   0.92       0.84          0.62 (0.34--1.13)   0.12     0.66     0.62 (0.39--1.00)   0.05   0.70     0.88 (0.57--1.35)   0.56     0.68
  Age                                                                                                                                                                   
   Child       8    0.83 (0.61--1.14)   0.26       0.02          1.38 (0.86--2.23)   0.18     \<0.01   1.48 (0.86--2.53)   0.16   \<0.01   1.08 (0.91--1.28)   0.38     0.59
   Adult       7    1.46 (1.17--1.83)   \<0.01     0.14          1.42 (0.89--2.27)   0.14     0.01     1.12 (0.90--1.41)   0.30   0.11     1.43 (1.01--2.03)   0.04     0.02
  Subtype                                                                                                                                                               
   LL          12   1.05 (0.78--1.41)   0.74       \<0.01        1.73 (1.19--2.51)   \<0.01   \<0.01   1.62 (1.10--2.38)   0.01   \<0.01   1.28 (1.10--1.48)   \<0.01   0.05
   ML          5    1.12 (0.87--1.45)   0.37       0.22          0.95 (0.71--1.28)   0.74     0.30     0.90 (0.70--1.14)   0.37   0.84     1.07 (0.84--1.35)   0.60     0.14

**Notes:**

*P*~h~ value used to test the heterogeneity. If *P*~h~ \<0.05, the random-effects model was applied to combine the data, otherwise the fixed-effects model was selected.

**Abbreviations:** CI, confidence interval; LL, lymphocytic leukemia; ML, myeloid leukemia; N, number of studies; OR, odds ratio.
